Faculty profile

David Chatenet

ResearcherInstitut national de la recherche scientifique

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Institut national de la recherche scientifique directory, so their courses may be missing. Find their university profile.

David Chatenet

Researcher

Health Sciences

Institut national de la recherche scientifique

Quebec City, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
11 publications in the last five years, latest in 2026.
Senior (last) author on 1 recent paper, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2022.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Angiotensin Ii Receptors Biased Signaling Bivalent Ligands Cardiovascular Diseases G Protein-Coupled Receptors Gpcr Pharmacology Heterodimers Urotensin Ii

Latest papers

Network-based allosteric analysis of galectin-7: Key residues dictate functional communication and stability.
Protein science : a publication of the Protein Society · 2026
Structure-activity relationships of contulakin-G: Design, synthesis, and characterization of Thr10 analogs for pain modulation.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025
Enhanced Gαq Signaling in TSC2-Deficient Cells Is Required for Their Neoplastic Behavior.
American journal of respiratory cell and molecular biology · 2025

All 22 publications

Latest funding

Unraveling the therapeutic potential and pharmacological complexity of the urotensinergic system
CIHR · 2022 · Nominated PI
$975,375
Allosteric Modulation of the Urotensin Receptor with Small-Molecule Peptide Mimics
CIHR · 2019 · Co-investigator
$765,000
GAL-7-specific nanobodies for treatment of triple-negative breast cancer
CIHR · 2018 · Co-investigator
$371,024

All 4 grants and awards

22 publications.

Network-based allosteric analysis of galectin-7: Key residues dictate functional communication and stability.

Pham NTH, Paré A, Létourneau M, Fortier M, Chatenet D, St-Pierre Y, Lagüe P, Calmettes C, Doucet N

Protein science : a publication of the Protein Society2026

DOI: 10.1002/pro.70502 PMID: 41700699

Structure-activity relationships of contulakin-G: Design, synthesis, and characterization of Thr10 analogs for pain modulation.

Lanoie A, Ferková S, Caron-Duval É, Dallagnol JCC, Diarra S, Murza A, Tremblay A, Théroux L, Breault É, Ranjbaran A, Landry L, Côté J, Longpré JM, Boudreault PL, Chatenet D, Sarret P

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2025

DOI: 10.1016/j.biopha.2025.118664 PMID: 41130099

Enhanced Gαq Signaling in TSC2-Deficient Cells Is Required for Their Neoplastic Behavior.

Tréfier A, Tousson-Abouelazm N, Yamani L, Ibrahim S, Joung KB, Pietrobon A, Yockell-Lelievre J, Hébert TE, Ladak RJ, Takano T, Nellist M, Namkung Y, Chatenet D, Stanford WL, Laporte SA, Kristof AS

American journal of respiratory cell and molecular biology2025

DOI: 10.1165/rcmb.2024-0111oc PMID: 39514407

Pharmacological characterization of cannabidiol as a negative allosteric modulator of the 5-HT2A receptor.

Billard E, Torbey A, Inserra A, Grant E, Bertazzo A, De Gregorio D, Comai S, Chatenet D, Gobbi G, Hébert TE

Cellular signalling2025

DOI: 10.1016/j.cellsig.2025.111588 PMID: 39761844

Expanding Structure-Activity Relationships of Human Urotensin II Peptide Analogues: A Proposed Key Role of the N-Terminal Region for Novel Urotensin II Receptor Modulators.

Merlino F, Secondo A, Mitidieri E, Sorrentino R, Bellavita R, Grasso N, Chatenet D, Pannaccione A, Grieco P, d'Emmanuele di Villa Bianca R, Carotenuto A

Journal of medicinal chemistry2024

DOI: 10.1021/acs.jmedchem.4c00688 PMID: 39096311

Evidence for heterodimerization and functional interaction of the urotensin II and the angiotensin II type 1 receptors.

Nassour H, Pétrin D, Devost D, Billard E, Sleno R, Hébert TE, Chatenet D

Cellular signalling2024Senior author

DOI: 10.1016/j.cellsig.2024.111056 PMID: 38262555

Urotensin II Receptor Modulation with 1,3,4-Benzotriazepin-2-one Tetrapeptide Mimics.

Wei X, Diarra S, Douchez A, Cunico Dallagnol JC, Hébert TE, Chatenet D, Lubell WD

Journal of medicinal chemistry2023

DOI: 10.1021/acs.jmedchem.3c01307 PMID: 37800680

G Protein-Biased Agonists for Intracellular Angiotensin Receptors Promote Collagen Secretion in Myofibroblasts.

Dallagnol JCC, Volkovich M, Chatenet D, Allen BG, Hébert TE

ACS chemical biology2023

DOI: 10.1021/acschembio.3c00319 PMID: 37611227

Placental Galectins in Cancer: Why We Should Pay More Attention.

Fuselier C, Dumoulin A, Paré A, Nehmé R, Ajarrag S, Granger Joly de Boissel P, Chatenet D, Doucet N, St-Pierre Y

Cells2023

DOI: 10.3390/cells12030437 PMID: 36766779

The complicated lives of GPCRs in cardiac fibroblasts.

Mazarura GR, Dallagnol JCC, Chatenet D, Allen BG, Hébert TE

American journal of physiology. Cell physiology2022

DOI: 10.1152/ajpcell.00120.2022 PMID: 35938678

Something wrong or missing on this profile? Suggest a correction

David Chatenet

Research

Latest papers

Latest funding

Network-based allosteric analysis of galectin-7: Key residues dictate functional communication and stability.

Structure-activity relationships of contulakin-G: Design, synthesis, and characterization of Thr10 analogs for pain modulation.

Enhanced Gαq Signaling in TSC2-Deficient Cells Is Required for Their Neoplastic Behavior.

Pharmacological characterization of cannabidiol as a negative allosteric modulator of the 5-HT2A receptor.

Expanding Structure-Activity Relationships of Human Urotensin II Peptide Analogues: A Proposed Key Role of the N-Terminal Region for Novel Urotensin II Receptor Modulators.

Evidence for heterodimerization and functional interaction of the urotensin II and the angiotensin II type 1 receptors.

Urotensin II Receptor Modulation with 1,3,4-Benzotriazepin-2-one Tetrapeptide Mimics.

G Protein-Biased Agonists for Intracellular Angiotensin Receptors Promote Collagen Secretion in Myofibroblasts.

Placental Galectins in Cancer: Why We Should Pay More Attention.

The complicated lives of GPCRs in cardiac fibroblasts.

Unraveling the therapeutic potential and pharmacological complexity of the urotensinergic system

Allosteric Modulation of the Urotensin Receptor with Small-Molecule Peptide Mimics

GAL-7-specific nanobodies for treatment of triple-negative breast cancer

Allosteric modulation of the urotensin receptor with small molecules

Frequent collaborators

Yves St-Pierre

Charles Calmettes

Pierre-Luc Boudreault

Gabriella Gobbi

Philippe Sarret

Adel Schwertani

Stanley Nattel

Tomoko Takano

David Chatenet

Research

Latest papers

Latest funding

Network-based allosteric analysis of galectin-7: Key residues dictate functional communication and stability.

Structure-activity relationships of contulakin-G: Design, synthesis, and characterization of Thr10 analogs for pain modulation.

Enhanced G&#x3b1;q Signaling in TSC2-Deficient Cells Is Required for Their Neoplastic Behavior.

Pharmacological characterization of cannabidiol as a negative allosteric modulator of the 5-HT2A receptor.

Expanding Structure-Activity Relationships of Human Urotensin II Peptide Analogues: A Proposed Key Role of the N-Terminal Region for Novel Urotensin II Receptor Modulators.

Evidence for heterodimerization and functional interaction of the urotensin II and the angiotensin II type 1 receptors.

Urotensin II Receptor Modulation with 1,3,4-Benzotriazepin-2-one Tetrapeptide Mimics.

G Protein-Biased Agonists for Intracellular Angiotensin Receptors Promote Collagen Secretion in Myofibroblasts.

Placental Galectins in Cancer: Why We Should Pay More Attention.

The complicated lives of GPCRs in cardiac fibroblasts.

Unraveling the therapeutic potential and pharmacological complexity of the urotensinergic system

Allosteric Modulation of the Urotensin Receptor with Small-Molecule Peptide Mimics

GAL-7-specific nanobodies for treatment of triple-negative breast cancer

Allosteric modulation of the urotensin receptor with small molecules

Frequent collaborators

Yves St-Pierre

Charles Calmettes

Pierre-Luc Boudreault

Gabriella Gobbi

Philippe Sarret

Adel Schwertani

Stanley Nattel

Tomoko Takano

Enhanced Gαq Signaling in TSC2-Deficient Cells Is Required for Their Neoplastic Behavior.